Genetic distance

Moolec Science Presents Third Quarter Fiscal Year 2024 Business Update

Retrieved on: 
Giovedì, Maggio 30, 2024
USDA, Fiscal, Yoy, Conference call, RSR, Conference, Chymosin, MLEC, Seed, Genetic distance, ID, Plant

Luxembourg, May 30, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.

Key Points: 
  • Luxembourg, May 30, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the third quarter of Fiscal Year 2024 ended March 31, 2024.
  • The main highlights of Moolec's business update are as follows:
    - Piggy Sooy?
  • - Financial highlight: Normalized revenues and other income (Ex-IAS 29) up ~$1.3M YoY given consolidation of soy-protein ingredient business.
  • For a full version of Moolec's first quarter Fiscal Year 2024 Business Update, click here.

Molecular Farming Company to Achieve USDA Approval for Plant-Grown Animal Proteins

Retrieved on: 
Lunedì, Aprile 22, 2024
FDA, Piggy, RSR, Seed, Risk, Myoglobin, Genetic engineering, USDA, Carbon, Animal, Plant, CFR, Movement, Membrane protein, Genetic distance, APHIS, Biotechnology

Luxembourg, Apr 22, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC)("The company"), a Molecular Farming food-ingredient company, announced today that the Animal and Plant Health Inspection Service ("APHIS") of the U.S. Department of Agriculture ("USDA") has concluded its Regulatory Status Review ("RSR") for Moolec's genetically engineered ("GE") soybean Piggy Sooy(TM).

Key Points: 
  • Luxembourg, Apr 22, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC)("The company"), a Molecular Farming food-ingredient company, announced today that the Animal and Plant Health Inspection Service ("APHIS") of the U.S. Department of Agriculture ("USDA") has concluded its Regulatory Status Review ("RSR") for Moolec's genetically engineered ("GE") soybean Piggy Sooy(TM).
  • The USDA-APHIS RSR determines that Moolec's genetically engineered soybean, accumulating animal meat protein, is unlikely to pose an increased plant pest risk relative to non-engineered soybeans.
  • We achieved an unprecedented milestone in biotechnology with the first-ever USDA-APHIS approval of this kind," stated Gaston Paladini, Moolec Science's CEO & Co-Founder.
  • By adding a well-known animal meat protein (porcine myoglobin) to the standard soybean proteins, the company expects to provide food manufacturers with a unique ingredient that will have a positive carbon and water footprint.

Exagen Inc. Announces Changes to the Board of Directors

Retrieved on: 
Venerdì, Aprile 26, 2024
University, Commoner, Rady Children's Hospital, Hospital, Champaign–Urbana metropolitan area, Churchill College, Cambridge, XGN, Privacy, SVP, Genetic distance, Growth, Postdoctoral researcher, Management

CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.

Key Points: 
  • CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.
  • Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director.
  • “First, I want to thank Brian Birk, Beto Pallares, Ph.D. and Wendy Johnson for their years of commitment and service to the Exagen Board of Directors.
  • To ensure we are well-equipped to grow with these changes, we have appointed Dr. Kahn to our Board of Directors.

Molecular Farming Global Markets Report 2024: Increasing Demand from the Pharmaceutical Industry for Proteins and Growing Use of Enzymes Fueling Expansion - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Martedì, Aprile 30, 2024
Health, Agriculture, Natural Resources, Research, Pharmaceutical, Science, Genetic distance, Investment, ESG, Fine chemical

The global market trends in molecular farming, including revenue data for 2022, estimated figures for 2023, and forecasts for 2027-2028, are analyzed alongside projected compound annual growth rates (CAGRs) through 2028.

Key Points: 
  • The global market trends in molecular farming, including revenue data for 2022, estimated figures for 2023, and forecasts for 2027-2028, are analyzed alongside projected compound annual growth rates (CAGRs) through 2028.
  • Insights into funding and investments in the molecular farming industry are provided, including coverage of ecofriendly production processes.
  • The report includes information on the latest developments in the industry, research and development activities, upcoming technologies, and economic trends.
  • This report offers a comprehensive look at the molecular farming industry and the end-use industries for its products.

Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists

Retrieved on: 
Mercoledì, Aprile 10, 2024
Canaccord Genuity, FSHD, Genetic distance, SAN

SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.
  • Institutional investors should contact their Canaccord representatives for additional information or to view the replay.

Immunome Appoints Sandra M. Swain to Board of Directors

Retrieved on: 
Giovedì, Aprile 25, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, MedStar Health, University, Bangladesh Technical Education Board, Pfizer, Genetic distance, Professor, Vanderbilt University, Doctor of Philosophy, National Cancer Institute, Dean (education), IND, ASCO, Patient, National Institutes of Health, Society, Acquisition, Executive Committee, Georgetown University Medical Center, Internal medicine, Investigational New Drug

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.
  • “Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • Dr. Swain served on the board of directors of the American Society of Clinical Oncology (ASCO) from 2008-2013 and was ASCO President 2012-13.
  • Dr. Swain previously served on the board of directors of Seagen Inc. from November 2022 until its acquisition by Pfizer Inc. in December 2023.

Jacques Banchereau, PhD Appointed as Chief Scientific Officer at Javelin Biotech

Retrieved on: 
Mercoledì, Aprile 17, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Javelin, Yale school, Roche, Tissue, Professor, Doctor of Philosophy, Yale School of Medicine, Genetic distance, CSO, Drug discovery, Pharmaceutical industry

Javelin Biotech, Inc., a leading technology company specializing in human tissue chip platforms for biopharma research, is delighted to announce the appointment of Jacques Banchereau, PhD as its Chief Scientific Officer (CSO).

Key Points: 
  • Javelin Biotech, Inc., a leading technology company specializing in human tissue chip platforms for biopharma research, is delighted to announce the appointment of Jacques Banchereau, PhD as its Chief Scientific Officer (CSO).
  • In his role at Javelin Biotech, Banchereau will oversee the company's scientific strategy, leveraging his vast experience and expertise to drive the development of cutting-edge technology for the modeling of human diseases.
  • "We are thrilled to welcome Jacques to the Javelin Biotech team," said Murat Cirit, PhD, CEO of Javelin Biotech.
  • Banchereau expressed his excitement about joining Javelin Biotech, stating, "I am honored to be part of a company that is dedicated to pushing the boundaries of scientific research.

ALPINE BIO, MAKER OF NOBELL FOODS, SECURES 10TH U.S. PATENT, BOLSTERING ITS PLATFORM AND DEMONSTRATING ITS LEADERSHIP IN MOLECULAR FARMING

Retrieved on: 
Martedì, Aprile 16, 2024
Breakthrough Energy, Agriculture, Genetic distance, Milk, Climate, Animal, Love, Taste, Plant, Patent, Food, Movement, SAN, Dairy

This milestone represents a significant stride in making animal-free dairy more accessible and appealing to consumers.

Key Points: 
  • This milestone represents a significant stride in making animal-free dairy more accessible and appealing to consumers.
  • Nobell Foods has been on a mission to unlock a new age of animal-free products where taste, quality, and affordability are widely accessible.
  • With further advances in Alpine Bio's end-to-end platform for protein production, Nobell Foods is even closer to bringing animal-free cheese to the world.
  • Strengthening Alpine Bio's robust IP portfolio, this patent further demonstrates the company's novel approach to revolutionizing the future of food with cheese that is produced without animals.

ACMG Foundation for Genetic and Genomic Medicine Elects Four Highly Accomplished Medical Genetics Professionals to its Board of Directors

Retrieved on: 
Giovedì, Aprile 11, 2024
Education, Disorder, Rady Children's Hospital, Entrepreneurship, Doctor of Philosophy, Pathology, ACMG, Medical director, American Academy, Veterinarian, Myriad Genetics, FACMG, Drug, Genetic testing, Baylor College of Medicine, Distinguishing, International HapMap Project, New York University, Clinical Pediatrics, National academy, Hospital, Hispanic, Book, Health, American Medical Association, Research, Pediatrics (journal), Mental health, Master of Science, Genetic distance, Pediatrics, Women's health, School, Washington State University, Society, Cancer, Partnership, Genomics, American College, Policy, Genetic, Disability studies, Developmental Biology (journal), Friends, Patient, MED, MBA, Baylor University

The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.

Key Points: 
  • The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.
  • The board members are active participants, serving as advocates for the ACMG Foundation and for advancing its policies and programs.
  • ACMG Foundation President Nancy J. Mendelsohn, MD, FACMG said, "We are pleased to welcome these four new members to the ACMG Foundation Board of Directors.
  • "I am honored for the opportunity to serve the ACMG again through participation in the Foundation Board of Directors.

Moolec Science Presents Second Quarter Fiscal Year 2024 Business Update

Retrieved on: 
Mercoledì, Marzo 13, 2024
4M, Conference, Farmer, Growth, MLEC, Research, Seed, Genetic distance, Marketing, Plant, Conference call, Myoglobin, Quarter, Fiscal, Internet service provider

Luxembourg, Mar 13, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the second quarter of Fiscal Year 2024 ended December 31, 2023.

Key Points: 
  • Luxembourg, Mar 13, 2024 - (ACN Newswire) - Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today its Business Update for the second quarter of Fiscal Year 2024 ended December 31, 2023.
  • The main highlights of Moolec's business update are as follows:
    - SOOY1 | Piggy Sooy(TM) Platform: Third generation (T3) soybean seed propagation has started, and fourth generation (T4) seeds are expected to be harvested in April 2024.
  • - PEEA1: Scientific team confirms the presence of bovine myoglobin gene in pea seeds and the gene's stable inheritance across plant generations.
  • Thank you to the Moolers, and to our partners for their continued support," stated Gaston Paladini, Chief Executive Officer and Co-Founder of Moolec Science.